American Cyanamid Company

Qlt Inc.

Qlt Phototherapeutics, Inc.

Narendra Raghunathji Desai

Madurai G Ganesan

Bushra J Agha

Kalidas Madhavrao Kale

James R Lawter

Eugene A Carpentier

Edward C Shinal

Prakash S Kulkarni

Gary A Maier

Liposomal pharmaceutical formulations incorporating porphyrin photosensitizers useful for photodynamic therapy or diagnosis of malignant cells. The liposomal formulations comprise a porphyrin photosensitizer, particularly the hydro-mono benzoporphyrins (BPD) having light absorption maxima in the range of 670&#x2013;780 nanometers, a disaccharide or polysaccharide and one or more phospholipids.

Liposome compositions of porphyrin photosensitizers

Liposomal pharmaceutical formulations incorporating porphyrin photosensitizers useful for photodynamic therapy or diagnosis of malignant cells. The liposomal formulations comprise a porphyrin photosensitizer, particularly the hydro-mono benzoporphyrine (BPD) having light absorption maxima in the range of 670-780 nanometers, a disaccharide or polysaccharide and one or more phospholipids.

Liposomal pharmaceutical formulations incorporating porphyrin photosensitizers useful for photodynamic therapy or diagnosis of malignant cells. The liposomal formulations comprise a porphyrin photosensitizer, particularly the hydro-mono benzoporphyrins (BPD) having light absorption maxima in the range of 670-780 nanometers, a disaccharide or polysaccharide and one or more phospholipids.

Complex of 1,4-dihydropyridine with polyoxyethylene-polyoxypropylene copolymer useful in sustained release dosage formulations.

Sustained release delivery system for substituted dihydropyridine

Lipid emulsion form compositions have been formulated and presented to eliminate adverse injection site reactions associated with the intravenous administration of certain sparingly water soluble, hydrophobic, ionizable drugs in mammals and to provide a solubilized drug form for oral, parenteral or intraarticular administration which enhances drug absorption and the therapeutic efficacy of the drug.

Emulsion compositions for administration of sparingly water soluble

This disclosure describes quick breaking, in vivo, intravenous, intramuscular, intraarticular fat emulsion compositions which incorporate the use of benzyl alcohol as a consurfactant and/or a cosolvent in combination with materials such as synthetic surfactants, e.g. sorbitan triisostearate, triglycerol diisostearate or triglycerol pentaoleate; naturally occurring vegetable oils, e.g. sesame oil, and soybean oil; natural lecithins such as egg lecithin or soy lecithin; saturated or unsaturated aliphatic acids, e.g. oleic acid, hexanoic acid and linolenic acid; and other excipients such as glycerine, polyvinylpyrrolidone, Pluronic.RTM. F-68 and di-.alpha.-tocopherol.

Growing community of inventors

Danbury, CT, United States of America

Narendra Raghunathji Desai